http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2305095-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_966a6c1f382ec9bcb5e3839dfd73e5b8 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D233-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D233-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4164 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D409-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D233-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-422 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4164 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D409-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-501 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-454 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4545 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D233-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D233-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D233-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 |
| filingDate | 2002-12-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2007-08-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_30a613c6b714579a401789fdcc89d61a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0f7f51c88b4228a436b98dc23490aff4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9c30717ee3195ef2f0f079a965bac14c |
| publicationDate | 2007-08-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2305095-C2 |
| titleOfInvention | Cis-2,4,5-triphenylimidazolines and pharmaceutical composition based on thereof |
| abstract | FIELD: organic chemistry, medicine, pharmacy. n SUBSTANCE: invention relates to novel compounds of the formula (I): wherein R means -C(O)R 1 wherein R 1 is chosen from the series: (C 1 -C 6 )-alkyl, -C=CH-COOH, -NHCH 2 -CH 2 R 2 , -N(CH 2 -CH 2 OH)CH 2 -CH 2 OH, -N(CH 3 )CH 2 -CH 2 -NHCH 3 , -N(CH 3 )CH 2 -CH 2 N(CH 3 )CH 3 , saturated 4-, 5- and 6-membered cycles and saturated and unsaturated 5- and 5-membered cycles comprising at least one heteroatom from a series sulfur (S), nitrogen (N) and oxygen (O), and optionally substituted with a group chosen from the series: (C 1 -C 6 )-alkyl, -C=O-R 5 , -OH, (C 1 -C 6 )-alkyl substituted with hydroxy-group optionally, (C 1 -C 6 )-alkyl substituted optionally with a group of the series: -NH 2 , -N-(C 1 -C 6 )-alkyl, -SO 2 CH 3 , =O, and 5- and 6-membered saturated cycles comprising at least one heteroatom chosen from N and O, and wherein R 5 is chosen from the series: hydrogen atom (H), (C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkyl substituted with hydroxy-group optionally, and (C 1 -C 6 )-alkyl substituted with NH 2 -group optionally; R 2 is chosen from the series: -N(CH 3 )CH 3 , -NH 2 , morpholinyl and piperazinyl; X 1 , X 2 and X 3 are chosen independently from the series: -OH, (C 1 -C 2 )-alkyl, (C 1 -C 6 )-alkoxy-group, -Cl, -Br, -F, -CH 2 OCH 3 and -CH 2 OCH 2 CH 3 , or one among X 1 , X 2 or X 3 means hydrogen atom, and two others are chosen independently from the series: hydroxy-group, (C 1 -C 6 )-alkyl, (C 1 -C 6 )-alkoxy-group, -Cl, -Br, -F, -CF 3 , -CH 2 OCH 3 , -CH 2 OCH 2 CH 3 , -OCH 2 -CH 2 R 3 , -OCH 2 -CF 3 and -OR 4 , morpholylmethyl, -N(CH 3 )CH 3 , -CH 2 OH, -COOH, or one among X 1 , X 2 or X 3 means hydrogen atom, and two others in common with two carbon atoms including bonds between them in benzene cycle to which they are bound optionally form 5- or 6-membered saturated cycle comprising at least one heteroatom chosen from S, N and O, and wherein R 3 is chosen from the series: -F, -OCH 3 , -N(CH 3 )CH 3 , saturated 5-membered cycle comprising at least one heteroatom N; R 4 means 3-5-membered saturated cycle, and each Y 1 and Y 2 is chosen independently from the series: -Cl, -Br, -NO 2 ,-C≡N and C≡N, and compound of the formula (II) also given in the invention description. Also, invention relates to a pharmaceutical composition possessing anti-proliferative activity and based on these compounds. Invention provides preparing novel compounds possessing the useful biological properties. n EFFECT: valuable medicinal properties of compounds and pharmaceutical composition. n 28 cl, 39 ex |
| priorityDate | 2001-12-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 654.